Project Funding

Funding for the RareConnect project comes from several types of sources such as patient organisations (AFM), public funds (EAHC), corporate syndicates (LEEM) and pharmaceutical companies. All funding supports the project as a whole and plays an essential part in launching and sustaining all participating rare disease communities.

Written by RareConnect team, published over 2 years ago.

AFM (French Association for Neuromuscular Disorders)
LEEM (Les Entreprises du medicament)

European Commission DG Health and Consumers
Alexion Pharmaceuticals
Celgene Corporation

CSL Behring

GSK
Millennium, The Takeda Oncology Company
Novartis
Pfizer
Medtronic Foundation

The material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.

Written by RareConnect team, published over 2 years ago.

Comments are closed.